sapanisertib   Click here for help

GtoPdb Ligand ID: 7933

Synonyms: INK 128 | INK-128 | INK128 | MLN0128 | TAK-228
PDB Ligand Antimalarial Ligand
Compound class: Synthetic organic
Comment: Sapanisertib (INK128) is an ATP-competitive inhibitor of mTOR in mTORC1 and mTORC2 complexes, that exhibits potent anti-tumour activity [2-4].

The compound also has antimalarial activity. The Malaria tab on this ligand page provides additional curator comments of relevance to the Guide to MALARIA PHARMACOLOGY.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 2
Topological polar surface area 121.67
Molecular weight 309.13
XLogP 1.9
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES Nc1oc2c(n1)cc(cc2)c1nn(c2c1c(N)ncn2)C(C)C
Isomeric SMILES Nc1oc2c(n1)cc(cc2)c1nn(c2c1c(N)ncn2)C(C)C
InChI InChI=1S/C15H15N7O/c1-7(2)22-14-11(13(16)18-6-19-14)12(21-22)8-3-4-10-9(5-8)20-15(17)23-10/h3-7H,1-2H3,(H2,17,20)(H2,16,18,19)
No information available.
Summary of Clinical Use Click here for help
INK-128 has has shown broad preclinical anti-tumour activity against a range of solid tumors [5]. Multiple Phase 2 clinical trials have been registered with These include studies in patients with metastatic anaplastic thyroid cancer (NCT02244463), metastatic castration-resistant prostate cancer (NCT02091531), ER/PR+ve/HER2-ve breast cancer (in combination with exemestane or fulvestrant in postmenopausal women; NCT02049957), refractory/unresectable pancreatic neuroendocrine carcinoma (NCT028939300) and relapsed/refractory ALL (NCT02484430). Click here to link to the complete list of sapanisertib/MLN0128/Tak-228/INK-128 clinical trials @